BLSM Stock Forecast & Price Target

BlossomHill Therapeutics is supported by a lead asset, BH-30643, that has shown encouraging early clinical activity in heavily pretreated EGFR-mutant NSCLC, including partial responses in 53% of 2L+ C797S+ patients without prior chemotherapy and 78% in TKI-naïve EGFR+ patients, alongside plasma exposures above target and a differentiated safety profile. The company also has multiple shots on goal, with BH-30236 producing ≥50% marrow blast reductions in 28.6% of assessed patients and a 36% ORR in R/R AML, while BH-501284 adds preclinical KRAS optionality, strengthening the longer-term pipeline beyond the near-term EGFR opportunity. Financially, BlossomHill ended 2Q26 with $95M in cash and equivalents and $168M of IPO proceeds, supporting an estimated runway into 2Q28 with zero revenue modeled for 2026 and 2027, which reduces dilution risk as catalysts approach.

BlossomHill Therapeutics is burdened by a high-risk, pre-commercial profile, with value still tied almost entirely to BH-30643 while the company remains unprofitable and may not reach profitability until the early 2030s, assuming FDA approval. The lead asset’s clinical path still faces meaningful execution risk: an EOP1 meeting is only anticipated in 4Q this year, an initial pivotal global Phase 2 is only potentially starting in 1Q27, and the program has shown dose-limiting liabilities such as bilirubin elevation and Grade ≥3 ALT/AST events. Beyond BH-30643, the rest of the pipeline is too early to offset concentration risk, as BH-30236 is still being evaluated in AML/HR-MDS and BH-501284 remains preclinical, leaving significant funding, dilution, regulatory, and competitive pressures unresolved.